Proposed mechanisms include enhanced T-cell activation against shared antigens between tumor and host tissues, reduced peripheral tolerance due to PD-1/PD-L1 blockade, and cross-reactivity between cardiac or skeletal muscle epitopes and tumor neoantigens (3). This evidence concerns the gene CD274 and neoplasm.